Novo Nordisk Is a Strong Buy After the 2025 Pullback

Novo Nordisk (NVO) is identified as a rare long-term buying opportunity in 2025, despite a significant stock decline exceeding 50% from its 2024 peak and facing headwinds such as increased GLP-1 competition and a lowered company outlook. This outlook is underpinned by robust Q2 2025 financials, including $11.68 billion in revenue and $4.03 billion in net income, alongside breakthrough clinical data from the STEER study demonstrating Wegovy's 57% reduction in cardiovascular events, uniquely positioning it among GLP-1s for obese patients without diabetes. Technically, the stock is approaching critical long-term support levels between $44 and $30, with a recent rebound from the $44 zone in Q3 2025 suggesting a potential bottom and a strong bullish reversal.

Analysis

Novo Nordisk (NVO) is presented at a pivotal juncture following a significant price correction of over 50% from its 2024 peak. This decline is contextualized by near-term headwinds, including a company-issued reduction in its sales and profit outlook for the second half of 2025, citing slower GLP-1 market expansion and the persistent use of compounded alternatives in the US. These internal challenges are compounded by external pressures such as rising competition, potential US tariffs, and a lowered 2025 growth forecast from Denmark's government, which noted pressure on the pharmaceutical sector. However, these concerns are strongly counterbalanced by robust fundamental and clinical catalysts. Financially, the company demonstrated resilience in Q2 2025 with revenue reaching $11.68 billion and net income at $4.03 billion, supported by a strong operating margin of 43.55% and broad-based sales growth in both US (+17%) and international (+19%) markets. Critically, new clinical data from the STEER study provides a significant competitive advantage, showing Wegovy reduced the risk of major cardiovascular events by 57% compared to Eli Lilly's Zepbound, establishing it as the only GLP-1 with proven cardiovascular protection in obese patients without diabetes. From a technical standpoint, the stock is approaching a historically significant support zone between $30 and $44, a confluence of a long-term trendline and the 78.6% Fibonacci retracement level. A notable rebound from this zone in Q3 2025 suggests a bottoming process may be underway, framing the correction as a potential long-term buying opportunity.

Key Decisions for Investors

• Given the confluence of deep technical support between $30-$44 and strong fundamental underpinnings, investors could consider the current valuation an attractive entry point for a long-term position, with the potential to scale in further if the price tests the lower end of this support range.
• Monitor prescription data and payer formulary updates for Wegovy, as its unique cardiovascular benefit demonstrated in the STEER study is a key potential catalyst for market share gains and could offset the competitive pressures cited in the company's revised guidance.
• Investors should remain cautious of the articulated risks, including the pace of GLP-1 market growth, the impact of compounded drugs, and any regulatory or reimbursement policy changes, as these factors could challenge the pace of the stock's recovery.